BioJAMP

BioJAMP is the specialized biosimilar division of JAMP Pharma Group, a leading Canadian-owned pharmaceutical company based in Boucherville, Quebec. Launched to address the increasing demand for affordable biologic treatments, BioJAMP focuses on the development and commercialization of high-quality biosimilars within the Canadian market. The company maintains a significant strategic partnership with Alvotech to bring complex therapies to patients across therapeutic areas such as immunology and ophthalmology. BioJAMP's portfolio includes biosimilars for major reference products like Humira (adalimumab) and Stelara (ustekinumab). By offering cost-effective alternatives to reference biologics, BioJAMP plays a vital role in improving patient access and supporting the sustainability of the Canadian healthcare system.